Literature DB >> 32374043

Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.

Agnieszka Jaracz-Ros1, Guillaume Bernadat2, Pasquale Cutolo1, Carmen Gallego1, Martin Gustavsson3, Erika Cecon4, Françoise Baleux5, Irina Kufareva3, Tracy M Handel3, Françoise Bachelerie1, Angélique Levoye6,7.   

Abstract

Chemokines play critical roles in numerous physiologic and pathologic processes through their action on seven-transmembrane (TM) receptors. The N-terminal domain of chemokines, which is a key determinant of signaling via its binding within a pocket formed by receptors' TM helices, can be the target of proteolytic processing. An illustrative case of this regulatory mechanism is the natural processing of CXCL12 that generates chemokine variants lacking the first two N-terminal residues. Whereas such truncated variants behave as antagonists of CXCR4, the canonical G protein-coupled receptor of CXCL12, they are agonists of the atypical chemokine receptor 3 (ACKR3/CXCR7), suggesting the implication of different structural determinants in the complexes formed between CXCL12 and its two receptors. Recent analyses have suggested that the CXCL12 N-terminus first engages the TM helices of ACKR3 followed by the receptor N-terminus wrapping around the chemokine core. Here we investigated the first stage of ACKR3-CXCL12 interactions by comparing the activity of substituted or N-terminally truncated variants of CXCL12 toward CXCR4 and ACKR3. We showed that modification of the first two N-terminal residues of the chemokine (K1R or P2G) does not alter the ability of CXCL12 to activate ACKR3. Our results also identified the K1R variant as a G protein-biased agonist of CXCR4. Comparative molecular dynamics simulations of the complexes formed by ACKR3 either with CXCL12 or with the P2G variant identified interactions between the N-terminal 2-4 residues of CXCL12 and a pocket formed by receptor's TM helices 2, 6, and 7 as critical determinants for ACKR3 activation. ©2020 Society for Leukocyte Biology.

Entities:  

Keywords:  ACKR3; CXCL12; CXCR4; GPCR signaling; chemokine variants; pluridimensional efficacy

Mesh:

Substances:

Year:  2020        PMID: 32374043      PMCID: PMC7540625          DOI: 10.1002/JLB.2MA0320-383RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  62 in total

1.  Scalable molecular dynamics with NAMD.

Authors:  James C Phillips; Rosemary Braun; Wei Wang; James Gumbart; Emad Tajkhorshid; Elizabeth Villa; Christophe Chipot; Robert D Skeel; Laxmikant Kalé; Klaus Schulten
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

2.  The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes.

Authors:  Karl Balabanian; Bernard Lagane; Simona Infantino; Ken Y C Chow; Julie Harriague; Barbara Moepps; Fernando Arenzana-Seisdedos; Marcus Thelen; Françoise Bachelerie
Journal:  J Biol Chem       Date:  2005-08-17       Impact factor: 5.157

3.  Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine.

Authors:  A Amara; O Lorthioir; A Valenzuela; A Magerus; M Thelen; M Montes; J L Virelizier; M Delepierre; F Baleux; H Lortat-Jacob; F Arenzana-Seisdedos
Journal:  J Biol Chem       Date:  1999-08-20       Impact factor: 5.157

4.  Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1.

Authors:  G A McQuibban; G S Butler; J H Gong; L Bendall; C Power; I Clark-Lewis; C M Overall
Journal:  J Biol Chem       Date:  2001-09-24       Impact factor: 5.157

5.  Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7.

Authors:  Frederic Sierro; Christine Biben; Laura Martínez-Muñoz; Mario Mellado; Richard M Ransohoff; Meizhang Li; Blanche Woehl; Helen Leung; Joanna Groom; Marcel Batten; Richard P Harvey; Carlos Martínez-A; Charles R Mackay; Fabienne Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-05       Impact factor: 11.205

6.  Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding.

Authors:  Martin Gustavsson; Douglas P Dyer; Chunxia Zhao; Tracy M Handel
Journal:  Sci Signal       Date:  2019-09-10       Impact factor: 8.192

7.  Control of chemokine-guided cell migration by ligand sequestration.

Authors:  Bijan Boldajipour; Harsha Mahabaleshwar; Elena Kardash; Michal Reichman-Fried; Heiko Blaser; Sofia Minina; Duncan Wilson; Qiling Xu; Erez Raz
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

8.  Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells.

Authors:  K E Luker; S A Lewin; L A Mihalko; B T Schmidt; J S Winkler; N L Coggins; D G Thomas; G D Luker
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

9.  Structural basis of ligand interaction with atypical chemokine receptor 3.

Authors:  Martin Gustavsson; Liwen Wang; Noortje van Gils; Bryan S Stephens; Penglie Zhang; Thomas J Schall; Sichun Yang; Ruben Abagyan; Mark R Chance; Irina Kufareva; Tracy M Handel
Journal:  Nat Commun       Date:  2017-01-18       Impact factor: 14.919

10.  Control of cell migration in the development of the posterior lateral line: antagonistic interactions between the chemokine receptors CXCR4 and CXCR7/RDC1.

Authors:  Christine Dambly-Chaudière; Nicolas Cubedo; Alain Ghysen
Journal:  BMC Dev Biol       Date:  2007-03-29       Impact factor: 1.978

View more
  2 in total

1.  Immunoexpression of CXCL12 and CXCR4 in sporadic and Gorlin-Goltz syndrome-related odontogenic keratocysts.

Authors:  Wliana-Pontes de Lima; Allany-de Oliveira Andrade; Roberta-Barroso Cavalcante; Renato-Luiz-Maia Nogueira; Pollianna-Muniz Alves; Cassiano-Francisco-Weege Nonaka; Manuel-Antonio Gordón-Núñez
Journal:  J Clin Exp Dent       Date:  2022-05-01

2.  Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias.

Authors:  Yu-Chen Yen; Christopher T Schafer; Martin Gustavsson; Stefanie A Eberle; Pawel K Dominik; Dawid Deneka; Penglie Zhang; Thomas J Schall; Anthony A Kossiakoff; John J G Tesmer; Tracy M Handel
Journal:  Sci Adv       Date:  2022-07-13       Impact factor: 14.957

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.